Dr. Yi Chen

H.C. Wainwright & Co.

Recent Articles about Veru Inc.

Miami Biopharma Sells Part of Business and Begins New Clinical Trial 01/02/2025

Miami biopharmaceutical company Veru Inc. (VERU:NASDAQ) recently sold its FC2 Female Condom business for US$18 million, and has begun enrolling patients for its The Phase 2b QUALITY trial of enobosarm in combination with Wegovy (semaglutide) for sarcopenic obesity. Read on to see why one analyst gives this company a Buy rating.